Skip to content

Study · Ex vivo tissue · 1984

2 results

Thymulin (FTS-Zn) induced in vitro modulation of T cell subsets markers on lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients.

Faure G, Bene MC, Tamisier JN, Gaucher A, Duheille J

International journal of immunopharmacology1 Jan 1984Cited by 8 (Europe PMC)

PMID6332789 (opens in a new tab)DOI10.1016/0192-0561(84)90058-4 (opens in a new tab)PepBankPUB-06332789
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    Thymulin improved T-cell subset abnormalities in lymphocytes from eight of nine rheumatoid arthritis patients.

    In plain wordsIn lab tests, thymulin improved abnormal T-cell subsets in eight of nine rheumatoid arthritis cell samples.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    MixedT-cell subset abnormalities
    Study

    humann = 9

    lymphocytes from rheumatoid arthritis patients
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    T cell subsets alterations responsible for abnormal values of the OKT4 +/OKT8 + immunoregulatory ratio, were improved by in vitro incubation of the lymphocytes with synthetic thymulin in eight out of nine RA patients.
    1 context sentence
    Summary · context
    Perturbations in T cells and T cell subsets of peripheral blood lymphocytes were looked for, using monoclonal antibodies, in nine patients with rheumatoid arthritis (RA) and four patients with systemic lupus erythematosus (SLE).
  2. 02LabEx vivo tissueActivity measurement

    Thymulin did not significantly modify T-cell subset abnormalities in lymphocytes from systemic lupus erythematosus patients.

    In plain wordsIn lab tests, thymulin did not significantly change abnormal T-cell subsets in lupus lymphocyte samples.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeT-cell subset abnormalities
    Study

    humann = 4

    lymphocytes from systemic lupus erythematosus patients
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant modification occured for SLE patients' lymphocytes.
    2 context sentences
    Title · context
    Thymulin (FTS-Zn) induced in vitro modulation of T cell subsets markers on lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients.
    Summary · context
    Perturbations in T cells and T cell subsets of peripheral blood lymphocytes were looked for, using monoclonal antibodies, in nine patients with rheumatoid arthritis (RA) and four patients with systemic lupus erythematosus (SLE).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:55 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.